These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. Herfarth H; Barnes EL; Valentine JF; Hanson J; Higgins PDR; Isaacs KL; Jackson S; Osterman MT; Anton K; Ivanova A; Long MD; Martin C; Sandler RS; Abraham B; Cross RK; Dryden G; Fischer M; Harlan W; Levy C; McCabe R; Polyak S; Saha S; Williams E; Yajnik V; Serrano J; Sands BE; Lewis JD; Gastroenterology; 2018 Oct; 155(4):1098-1108.e9. PubMed ID: 29964043 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis. Naganuma M; Sugimoto S; Mitsuyama K; Kobayashi T; Yoshimura N; Ohi H; Tanaka S; Andoh A; Ohmiya N; Saigusa K; Yamamoto T; Morohoshi Y; Ichikawa H; Matsuoka K; Hisamatsu T; Watanabe K; Mizuno S; Suda W; Hattori M; Fukuda S; Hirayama A; Abe T; Watanabe M; Hibi T; Suzuki Y; Kanai T; Gastroenterology; 2018 Mar; 154(4):935-947. PubMed ID: 29174928 [TBL] [Abstract][Full Text] [Related]
14. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625 [TBL] [Abstract][Full Text] [Related]
15. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166 [TBL] [Abstract][Full Text] [Related]
16. A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis. Fiorino G; Sturniolo GC; Bossa F; Cassinotti A; di Sabatino A; Giuffrida P; Danese S Cells; 2019 May; 8(6):. PubMed ID: 31151306 [TBL] [Abstract][Full Text] [Related]
17. Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial. Shen Z; Zheng K; Zou J; Gu P; Xing J; Zhang L; Zhu L; Shen H Trials; 2021 Jan; 22(1):55. PubMed ID: 33441157 [TBL] [Abstract][Full Text] [Related]
18. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Sandborn WJ; Vermeire S; Peyrin-Biroulet L; Dubinsky MC; Panes J; Yarur A; Ritter T; Baert F; Schreiber S; Sloan S; Cataldi F; Shan K; Rabbat CJ; Chiorean M; Wolf DC; Sands BE; D'Haens G; Danese S; Goetsch M; Feagan BG Lancet; 2023 Apr; 401(10383):1159-1171. PubMed ID: 36871574 [TBL] [Abstract][Full Text] [Related]